Table 4.
Uni- and multivariate analyses of factors affecting time to treatment failure
| Variable | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | ||
| SMI | 1: high | ||||
| 2: low | 1.888 (1.154–3.089) | 0.011 | 1.716 (1.041–2.827) | 0.034 | |
| Age, years | 1: <75 | ||||
| 2: ≥75 | 1.306 (0.747–2.284) | 0.348 | |||
| Male sex | 1:- | ||||
| 2: + | 1.533 (0.879–1.790) | 0.128 | |||
| BW, kg | 1: <60 | 1.247 (0.779–1.997) | 0.357 | ||
| 2: ≥60 | |||||
| BCLC stage | 1: B | ||||
| 2: C | 1.228 (0.766–1.970) | 0.394 | |||
| BCAA supplementation | 1: − | ||||
| 2: + | 1.635 (0.891–2.998) | 0.112 | |||
| Previous therapy: transcatheter treatment | 1: − | ||||
| 2: + | 1.094 (0.609–1.967) | 0.763 | |||
| Previous therapy: molecularly targeted therapy | 1: − | ||||
| 2: + | 1.376 (0.857–2.207) | 0.186 | |||
| Refractory to transcatheter treatment | 1: − | ||||
| 2: + | 1.003 (0.626–1.607) | 0.990 | |||
| Alpha-fetoprotein, ng/mL | 1: <200 | ||||
| 2: ≥200 | 1.365 (0.849–2.197) | 0.199 | |||
| ALBI grade | 1: ≤-2.60 | 2.000 (1.163–3.439) | 0.012 | 1.817 (1.047–3.151) | 0.034 |
| 2: ≤-1.39 | 3.942 (1.756–8.850) | 0.001 | |||
| 3: >-1.39 | |||||
ALBI, albumin-bilirubin; BCAA, branched-chain amino acid; BCLC, Barcelona Clinic Liver Cancer; BW, body weight; CI, confidence interval; OR, odds ratio; SMI, skeletal muscle index.